title: Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone pulse therapy.
abstract: This preliminary study was undertaken to investigate the efficacy of high-dose iv methylprednisolone pulse therapy in 5 patients with Graves' ophthalmopathy. One gram of methylprednisolone sodium succinate was given iv daily for 3 successive days. The 3-day infusion was repeated 3 to 7 times at intervals of 1 week; total duration of pulse therapy was 3 to 7 weeks. The clinical improvement of eye involvements by pulse therapy was assessed immediately after the last pulse therapy. The clinical assessment of the effect of pulse therapy for Graves' ophthalmopathy showed a good response in 3 patients, a fair response in one, and no response in one. However, in one patient, who was judged to show no response, complete improvement of the enlarged extraocular muscle was observed on orbital computed tomography. Moreover, two patients, who have been followed without any other therapies, showed no relapse of eye involvements for 32 and 10 months, respectively. Although it is impossible to determine whether pulse therapy is more effective than other immunosuppressive therapies, the results of this preliminary study suggest that pulse therapy may be a good immunosuppressive therapy for Graves' ophthalmopathy too. Controlled studies are desired.
authors.affiliation: First Department of Internal Medicine, Nagasaki University School of Medicine, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Nagayama
authors.forename: M
authors.initials: M
authors.lastname: Izumi
authors.forename: T
authors.initials: T
authors.lastname: Kiriyama
authors.forename: N
authors.initials: N
authors.lastname: Yokoyama
authors.forename: S
authors.initials: S
authors.lastname: Morita
authors.forename: F
authors.initials: F
authors.lastname: Kakezono
authors.forename: S
authors.initials: S
authors.lastname: Ohtakara
authors.forename: I
authors.initials: I
authors.lastname: Morimoto
authors.forename: S
authors.initials: S
authors.lastname: Okamoto
authors.forename: S
authors.initials: S
authors.lastname: Nagataki
mesh_terms: D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D005260:Female; D006111:Graves Disease / Q000188:drug therapy*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008775:Methylprednisolone / Q000031:analogs & derivatives*; D008776:Methylprednisolone Hemisuccinate / Q000008:administration & dosage*; D008875:Middle Aged; D009801:Oculomotor Muscles / Q000473:pathology; D009915:Orbit / Q000000981:diagnostic imaging; D014057:Tomography, X-Ray Computed; D014787:Vision Tests
chemical_list: D008776:Methylprednisolone Hemisuccinate; D008775:Methylprednisolone